Alnylam Pharmaceuticals (ALNY) concentration risks

The company's concentration profile is anchored by a product dependency of moderate disclosed size. The filing notes that a significant portion of net product revenues was derived from the sale of TTR products, and in particular AMVUTTRA. That characterization places the exposure in the medium-share band by disclosed size, and the character is mixed — the reliance on a specific approved product reflects both the structural position of a company building commercial momentum behind a lead launch and the dependency risk of having revenue disproportionately tied to one branded franchise. Because the concentration is in a commercially launched product rather than a pre-approval pipeline asset, the risk profile differs from pure binary clinical-stage exposure. The key variables are revenue durability: competitive entries into TTR-related indications, pricing and reimbursement dynamics, and the pace at which AMVUTTRA's label expansions or new indications can broaden the revenue base. A competitor approval or label setback for AMVUTTRA would have a medium but meaningful effect on the disclosed revenue share. No customer, geographic, or supplier concentrations are separately disclosed. On balance, the profile is relatively narrow: a medium-share product dependency on a single commercial franchise, where the monitoring focus should be on competition in the TTR space and the company's progress diversifying revenues across its broader product portfolio.

For the engine’s reasoning on ALNY’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.